To hear about similar clinical trials, please enter your email below
Trial Title:
H19 in Acute Lymphoblastic Leukemia.
NCT ID:
NCT05943093
Condition:
Acute Lymphoid Leukemia
Conditions: Official terms:
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Retrospective
Summary:
- Study the expression level of H19 gene in the samples from ALL patients by real-time
PCR.
- Correlate the expression level of H19 gene with the clinical presentation and
laboratory data of those patients.
Detailed description:
Acute lymphoblastic leukemia (ALL) is the most common cancer affecting children and
adolescents (Zeng XL et al, 2023). ALL is a haematological malignancy characterized by
the malignant clonal expansion of lymphoid hematopoietic precursors (Hong Z et al, 2021).
It arises from B- or T-lineage lymphoid progenitors: B-cell-precursor ALL (B-ALL) and
T-cell ALL (T-ALL) (Brady SW et al., 2022). Rrelapse in ALL is the fundamental cause of
treatment failure in 15-20% of patients (Hulleman E et al, 2009). Therefore, the
exploration of novel functional molecules that play a role in ALL pathogenesis could be
effective therapeutic targets for this disease (Asadi M et al, 2023).
Long non-coding RNAs (lncRNAs) are non-protein coding transcripts longer than 200
nucleotides (Kopp F et al, 2018). H19 was the first lncRNA to be discovered and submitted
for genomic imprinting (Yoshimura H et al, 2018). It has a role in embryogenesis and
tumorigenesis (Yoshimura H et al, 2014). It also has an indispensable role in enhancing
cell proliferation, differentiation, migration, invasion, and chemo resistance (Li Y et
al, 2020). Recent evidence has shown that H19 is an oncogene and is overexpressed in
breast, liver, endometrial, lung, cervical, and esophageal cancers (Asadi M et al, 2023).
A similar pattern of H19 expression was observed in various types of leukemias, including
chronic myeloid leukemia (CML) (Morlando M et al, 2015) and acute myeloid leukemia (AML)
(Zhang Tj et al, 2018).
Criteria for eligibility:
Study pop:
newly diagnosed ALL patients
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Newly diagnosed ALL patients.
Exclusion Criteria:
- 1-Presence of other haematological disorders, history of other malignancies or
relapsed ALL.
2-Patients under chemotherapy or radiotherapy.
Gender:
All
Minimum age:
2 Months
Maximum age:
70 Years
Start date:
July 2023
Completion date:
August 2025
Lead sponsor:
Agency:
Assiut University
Agency class:
Other
Source:
Assiut University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05943093
https://pubmed.ncbi.nlm.nih.gov/36680478/
